Core Viewpoint - Beijing Shuanglu Pharmaceutical Co., Ltd. announced that its associate company, Changfeng Pharmaceutical Co., Ltd., is expected to be listed on the Hong Kong Stock Exchange on October 8, 2025, with a global offering of 41.198 million shares at a price of HKD 14.75 per share [1] Group 1 - The total number of shares offered in the global sale is 41.198 million [1] - The offering price per share is set at HKD 14.75 [1] - After the offering, Shuanglu Pharmaceutical will hold 15.165653 million shares of Changfeng Pharmaceutical, representing 3.68% of the total shares post-issuance [1] Group 2 - The lock-up period for Shuanglu Pharmaceutical's shares in Changfeng Pharmaceutical is 12 months [1] - According to regulations, Shuanglu Pharmaceutical will classify its equity stake in Changfeng Pharmaceutical as a financial asset [1] - The listing of Changfeng Pharmaceutical is expected to have a positive impact on Shuanglu Pharmaceutical's financial and operational results in 2025, subject to audit results [1]

Group 1 - The core point of the article is that Shuanglu Pharmaceutical (002038.SZ) announced that its associate company, Changfeng Pharmaceutical (02652), is expected to officially list on the Hong Kong Stock Exchange on October 8, 2025 [1] - Changfeng Pharmaceutical plans to offer a total of 41.198 million shares in its global offering, with a price set at HKD 14.75 per share [1]

Core Viewpoint - The company 双鹭药业 (002038.SZ) announced that its associate 长风药业 (02652) is expected to officially list on the Hong Kong Stock Exchange on October 8, 2025, with a global offering of 41.198 million shares priced at HKD 14.75 per share [1] Group 1 - 双鹭药业 holds a stake in 长风药业, which is preparing for its IPO [1] - 长风药业 plans to offer a total of 41.198 million shares in its global offering [1] - The offering price for each share is set at HKD 14.75 [1]

Group 1 - Double-Crane Pharmaceutical's associate company, Changfeng Pharmaceutical, is expected to officially list on the Hong Kong Stock Exchange on October 8, 2025, with stock code 02652.HK [1] - After the completion of the offering, Double-Crane Pharmaceutical will hold a total of 15.1657 million shares in Changfeng Pharmaceutical, which is expected to account for 3.68% of the total shares after issuance [1] Group 2 - LEO Holdings has submitted an application to the Hong Kong Stock Exchange on September 29, 2025, for the issuance of overseas listed shares (H shares) and for listing on the main board of the Hong Kong Stock Exchange [1]

Core Viewpoint - The announcement indicates that Changfeng Pharmaceutical, a company in which Shuanglu Pharmaceutical holds a stake, is expected to officially list on the Hong Kong Stock Exchange on October 8, 2025, under the stock code 02652.HK [1] Summary by Relevant Categories Company Information - Shuanglu Pharmaceutical holds 15,165,700 shares in Changfeng Pharmaceutical, which is expected to represent 3.68% of the total shares post-issuance [1] - Changfeng Pharmaceutical plans to globally offer 41,198,000 shares at a price of HKD 14.75 per share [1] Market Impact - The listing of Changfeng Pharmaceutical is anticipated to enhance Shuanglu Pharmaceutical's visibility and potential market valuation [1]

Core Viewpoint - Three new stocks, Xipuni, Zijin Gold, and Botai Che Lian, all experienced price increases during their dark pool trading, indicating positive market sentiment towards these IPOs [1][2]. Group 1: IPO Information - Longfeng Pharmaceutical (02652.HK) is set to issue 41.198 million shares, with 10% allocated for public sale and 90% for international placement, at an offering price of 14.75 HKD per share [4]. - The company has a market capitalization of approximately 60.77 billion HKD and a price-to-earnings ratio of 265 times [12]. - The minimum investment amount for a single lot of 500 shares is 7,449 HKD [4]. Group 2: Company Overview - Longfeng Pharmaceutical, established in January 2013 in Suzhou, focuses on the development of inhalation drug delivery technologies, particularly for respiratory diseases [4]. - The product pipeline includes treatments for asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis [4]. Group 3: Product Line and Market Performance - The core product CF017 (Budesonide inhalation suspension) is the top-selling inhalation drug in China, accounting for approximately 16% of the market share in 2024 [5][11]. - CF018 (Fluticasone nasal spray) is the first drug approved in China for moderate to severe allergic rhinitis, included in the national medical insurance directory as of December 2023 [6]. - Revenue from CF017 constituted 96.2% of total revenue in 2022, highlighting the company's reliance on a single product [9][10]. Group 4: Financial Performance - Longfeng Pharmaceutical's revenue grew from 349.1 million CNY in 2022 to an estimated 607.8 million CNY in 2024, with a compound annual growth rate of 31.9% [7]. - The company achieved profitability in 2023 with a net profit of 31.73 million CNY, but profits are projected to decline to 21.09 million CNY in 2024 [8]. Group 5: Competitive Landscape and Market Outlook - The market for budesonide products is becoming increasingly competitive, with nine products available in China as of 2025, including seven domestic brands [11]. - The global respiratory drug market is expected to grow from 99.9 billion USD in 2024 to 157.2 billion USD by 2033, with a compound annual growth rate of 5.2% [11]. - Longfeng Pharmaceutical is developing over 20 candidate products for global markets, including innovative therapies for CNS diseases and infections [11].

Core Viewpoint - The new IPO of Changfeng Pharmaceutical (02652) has raised a total of HKD 820.086 million, with an oversubscription rate exceeding 1343 times [1] Group 1: IPO Details - The total amount raised by Changfeng Pharmaceutical is HKD 820.086 million [1] - The company has received subscriptions from various brokers, including Futu, which contributed HKD 457 million, and Huasheng, which contributed HKD 26.8 million [1] - The overall subscription amount from other brokers totals HKD 158.535 million [1] Group 2: Subscription Performance - The IPO was significantly oversubscribed, with an oversubscription rate of over 1343 times [1] - The interest in the IPO indicates strong market demand for Changfeng Pharmaceutical's shares [1]

Summary of Key Points Core Viewpoint The Hong Kong stock market has seen significant activity from September 21 to September 27, with 25 companies submitting prospectuses, 3 companies passing hearings, and 2 new stocks successfully listed. Group 1: Companies Submitting Prospectuses - A total of 25 companies submitted listing applications to the Hong Kong Stock Exchange during the specified period, including major players like 大洋电机, 天赐材料, and 格林美 [2][4][5] - Notably, 12 of these companies have already listed on the A-share market, indicating a trend towards dual listings in both A and H shares [2][4] Group 2: Companies Passing Hearings - Three companies successfully passed hearings: 长风药业, 挚达科技, and 金叶国际 [30] - 长风药业 focuses on biopharmaceuticals for respiratory diseases, with projected revenues of 6.08 billion RMB in 2024 [31] - 挚达科技 is the largest provider of home electric vehicle charging stations globally, with revenues of 5.9 billion RMB in 2024 [32] - 金叶国际 is a long-established electromechanical engineering contractor, specializing in HVAC systems [33] Group 3: Companies in the IPO Process - Five companies are currently in the IPO process, including 长风药业, 紫金黄金国际, 西普尼, 博泰车联, and 奇瑞汽车 [34] - 奇瑞汽车 successfully listed on September 25, with a first-day stock price increase of 13.75% [41][43] Group 4: Financial Performance of Companies - 大洋电机 reported total revenues of approximately 109.3 billion RMB in 2022, with a projected increase to 121.13 billion RMB in 2024 [5] - 天赐材料's revenues were approximately 223.17 billion RMB in 2022, expected to decline to 125.18 billion RMB in 2024 [6] - 格林美's revenues were around 293.92 billion RMB in 2022, projected to reach 332.00 billion RMB in 2024 [7] - 万辰集团, a leading snack and beverage retailer, reported revenues of 5.49 billion RMB in 2022, with a significant increase to 323.29 billion RMB in 2024 [10] Group 5: Market Trends and Insights - The trend of companies seeking dual listings in both A and H shares is becoming more prevalent, reflecting a strategic move to access broader capital markets [2][4] - The overall activity in the Hong Kong IPO market indicates a robust interest from companies looking to capitalize on the favorable market conditions [2][30]

Core Viewpoint - The article discusses the IPO of Changfeng Pharmaceutical, highlighting its focus on inhalation technology and its product portfolio aimed at treating respiratory diseases. The company has received multiple product approvals from regulatory authorities, indicating a strong market position and growth potential [3][10]. Company Overview - Changfeng Pharmaceutical was established in 2013 and specializes in the research, development, production, and commercialization of inhalation drugs, particularly for respiratory diseases [3]. - The company's core product is an inhalation suspension of Budesonide for treating bronchial asthma, which accounts for over 90% of its revenue [6]. Financial Performance - Revenue projections for the company are as follows: CNY 349 million in 2022, CNY 556 million in 2023, and CNY 608 million in 2024, reflecting a compound annual growth rate (CAGR) of 31.9% [6]. - The company turned a profit in 2023 with a net profit of CNY 31.73 million, but is expected to see a decline in net profit to CNY 21.09 million in 2024, a year-on-year decrease of 33.5% due to increased sales expenses [6][7]. IPO Details - The IPO subscription period for Changfeng Pharmaceutical is from September 26 to October 2, with a global offering of 41.198 million shares at a price of HKD 14.75 per share [10]. - The offering includes 4.12 million shares available in Hong Kong, with a high demand indicated by nearly 500 times subscription, suggesting strong investor interest [10].

Group 1: Alibaba Group - CMB International maintains a "Buy" rating for Alibaba-SW, raising the target price to HKD 195, citing advancements in AI infrastructure investment of RMB 380 billion and a projected 10x increase in data center energy consumption by 2032 [1] - CICC also maintains an "Outperform" rating for Alibaba-SW, increasing the target price to HKD 197, highlighting the leading position of Tongyi model ecosystem and the potential for commercial value release [1] Group 2: Kuaishou Technology - UBS maintains a "Buy" rating for Kuaishou-W, setting a target price of HKD 95.37, noting significant advancements in the 可灵 2.5 Turbo model for text understanding and video generation [1] Group 3: Xiaomi Corporation - Daiwa Securities maintains a "Buy" rating for Xiaomi Group, with a target price of HKD 76, reporting an increase in weekly electric vehicle deliveries to 10,000-12,000 units and plans to enter the European market by 2027 [2] Group 4: Longwind Pharmaceutical - China Everbright Securities International highlights Longwind Pharmaceutical's strong growth prospects, focusing on inhalation technology and drug development, with six products approved in the respiratory disease field [3] Group 5: Nine Dragons Paper Holdings - Bank of America maintains a "Buy" rating for Nine Dragons Paper, setting a target price of HKD 6.5, with a projected net profit of RMB 1.767 billion for FY25 and a 9.7% increase in sales [3] - Shenwan Hongyuan also maintains a "Buy" rating, noting significant improvements in gross profit and net profit, with expected growth in net profit for 2026-2028 [4] - Guotai Junan raises the target price for Nine Dragons Paper to HKD 7.37, citing a 9.6% increase in sales and a 1.9 percentage point rise in gross margin [4] Group 6: Xindong Company - CMB Securities strongly recommends Xindong Company, highlighting the successful public testing of "伊瑟" and a 37.74% increase in revenue from the TapTap platform [5] Group 7: Mixue Group - CITIC Securities maintains a "Buy" rating for Mixue Group, emphasizing its efficient supply chain and membership growth exceeding 300 million, with plans for expansion in Southeast Asia and new global markets [6]